The global poultry vaccines market size was valued at USD 1.9 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.40% from 2023 to 2030. Growing product R&D, rising incidence of diseases in poultry, demand to secure food sources, and awareness and initiatives to curb antimicrobial resistance are some of the key drivers of this market. In 2019, HIPRA extended its coccidiosis vaccine lineup with the launch of EVANT - an attenuated vaccine for broilers.
The COVID-19 pandemic adversely impacted the poultry industry with dampened demand, low sales, unsold inventories, and a drop in prices of poultry meat and eggs. The impact was more pronounced in countries with large poultry populations such as India. Although egg production, dairy production, meat production was included in essential services, the lockdown and movement restrictions disrupted the supply chain. These hurdles combined with the emergence and fear of other avian diseases such as Bird flu in India exacerbated the adverse impact of the pandemic.
However, the COVID-19 pandemic has created opportunities for vaccine manufacturers that can be leveraged to gain market share. This is owing to the growing awareness regarding animal diseases, demand for safe food stock and products, and concerns over zoonoses. Venkys India, for instance, is a key market player involved in the production of SPF eggs, broiler and layer breeding, chicken and eggs processing, poultry feed and equipment, vaccine production, biosecurity products, and many more. The company offers a wide portfolio of poultry vaccines, which together with other poultry products contributed to a 45% revenue share in 2019.
The growing poultry population combined with the rising prevalence of avian diseases is expected to drive the demand for poultry vaccines. Infected meat consumption risks human health, thereby making it imperative that the birds be vaccinated before usage. The main obstacles faced by poultry farms are the rapid spread of diseases and the lack of treatment options. To prevent such situations, vaccination becomes mandatory. In 2019, the U.S. had 19.72 million livestock units of chicken, while Brazil had 14.6 million livestock units of chicken. The large poultry population indicates a significant number of poultry that is susceptible to avian diseases, which can be prevented with timely vaccinations.
According to the OIE-WAHIS database, there were a total of 22 new outbreaks in birds across the globe. This number rose sharply to 836 new outbreaks in 2020 with cases estimated at 2.79 million. The increasing incidence of disease outbreaks in the avian population is thus a key driver for the market. One of the most recent disease notifications includes low pathogenic avian influenza reported in poultry in Italy and highly pathogenic avian influenza reported in Russia in October 2021.
The attenuated live vaccines segment held the largest revenue share of over 30.0% in 2022. These types of vaccines can trigger the immune system to produce a greater number of antibodies as compared to other types of vaccines. Moreover, the duration of immunity lasts longer and protects against avian diseases such as infectious bronchitis, infectious bursal disease, and Newcastle disease. Moreover, growing R&D activities, particularly in this field of vaccination, to curb various outbreaks of the aforementioned diseases are accentuating the segment growth.
The recombinant vaccines and inactivated vaccines are one of the fastest growing segments in the coming years. The key factors contributing to this growth include product developments and safety benefits associated with inactivated and recombinant vaccines in comparison to live attenuated vaccines. Zoetis, for example, offers an extensive portfolio of vaccines for poultry under its Poulvac brand. The poultry segment contributed to 18% of the company’s livestock revenue in 2020.
The salmonella diseases segment accounted for the largest revenue share of over 8.0% in 2022. The Egg Drop Syndrome (EDS) segment is expected to expand at the fastest CAGR over the forecast period. This is owing to the high prevalence of Salmonella and Egg Drop Syndrome diseases in poultry animals. The most common type of vaccine for salmonella is the attenuated Salmonella strains, which can serve as effective as well as safe oral carrier vaccines for preventing necrotic enteritis by expressing heterologous antigens.
Market players are involved in the R&D and launch of new vaccines to increase their market presence and share. Venkys India, for example, offers a range of poultry vaccines that include the Salmonella polyvalent inactivated vaccine for prevention and control of salmonellosis in layers, breeders, and broilers. OILVAX EDS-76 is a part of the portfolio of KM Biologics and is effective against egg drop syndrome.
The breeder segment held the largest revenue share of over 35.0% in 2022. The breeder segment is expected to exhibit the fastest growth rate during the forecast period owing to the increasing number of breeder farms producing fertile eggs, which are hatched in a hatchery. Increased productivity through these breeding farms has fueled the growth of the market. The market growth can also be attributed to various government initiatives for the vaccination of breeders, as it not only protects the vaccinated birds, but also the progeny, i.e. the broilers.
The growth of breeder farms is mainly attributed to pro-active government policies, which have resulted in a growing number of poultry farmers, breeders and integrators, and feed mills. For instance, the Animal Husbandry Department in the state of Andhra Pradesh, India intensified production in the poultry sector through a comprehensive poultry development policy (2016-2020) in the state. The policy aimed to enhance the production from layers and commercial broilers and encourage the processing of eggs and chickens, thereby promoting export activities. Such favorable initiatives by the government are further driving the market.
Europe held the largest revenue share of over 20.0% in 2022. This is due to the presence of key players, growing initiatives against the use of antimicrobials in animals, and rising concerns over zoonoses. The World Health Organization (WHO) has identified Antimicrobial resistance as a public health threat. Many public health bodies and veterinary regulatory agencies such as the Committee for Medicinal Products for Veterinary Use (CVMP) are responsible for implementing the EU’s One Health Action Plan against antimicrobial resistance by deploying the policies of the Veterinary Medicines Regulation.
Asia Pacific is estimated to expand at the fastest CAGR of 8.0% over the forecast period. This is owing to the increasing awareness regarding poultry vaccines and a surge in the number of vaccination awareness programs. Other factors include rising government initiatives and rapid improvement in animal husbandry practices.
The market has been characterized by immense competition owing to the presence of local and global players trying to increase their penetration via different strategic moves such as new product development, M&A, JV, partnerships, and distribution channel agreements. For instance, in July 2019, Ceva acquired IDT Biologika GmbH’s veterinary biopharmaceutical as well as R&D business. Additionally, Boehringer Ingelheim launched the VAXXITEK HVT+IBD+ND vaccine in January 2020, to protect poultry against Newcastle Disease, Marek’s Disease, and Infectious Bursal Disease (classic and variant types). Some prominent players in the global poultry vaccines market include:
Boehringer Ingelheim International GmbH
Ceva
Zoetis
Elanco
Merck & Co., Inc.
Hester Biosciences Limited
Vaxxinova International BV
Venkys India
Calier
KM Biologics
Phibro Animal Health Corporation
Report Attribute |
Details |
Market size value in 2023 |
USD 2.0 billion |
Revenue forecast in 2030 |
USD 3.3 billion |
Growth rate |
CAGR of 7.40% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2017 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million & CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, product, disease type, region |
Regions covered |
North America; Europe; Asia Pacific; Latin America; MEA |
Country Scope |
U.S.; Canada; U.K.; Germany; Italy; France; Spain; Russia; Japan; China; India; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia |
Key companies profiled |
Boehringer Ingelheim International GmbH; Ceva; Zoetis; Elanco; Merck & Co., Inc.; Hester Biosciences Limited; Vaxxinova International BV; Venkys India; Calier; KM; Biologics; Phibro Animal Health Corporation |
Customization scope |
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For the purpose of this report, Grand View Research has segmented the global poultry vaccines market report on the basis of application, product, disease type, and region:
Application Outlook (Revenue, USD Million, 2017 - 2030)
Broiler
Layer
Breeder
Product Outlook (Revenue, USD Million, 2017 - 2030)
Attenuated Live Vaccines
Inactivated Vaccines
Subunit Vaccines
DNA Vaccines
Recombinant Vaccines
Disease Type Outlook (Revenue, USD Million, 2017 - 2030)
Infectious Bronchitis
Infectious Bursal Diseases
Infectious Laryngotracheitis
Egg Drop Syndrome
Adenovirus
Duck Viral Enteritis
Inclusion Body Hepatitis
Coccidiosis
Avian Influenza
Marek's Disease
Newcastle Disease
Salmonella
Avian Encephalomyelitis
Fowl Cholera
Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
China
India
Japan
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
b. The global poultry vaccines market size was estimated at USD 1.9 billion in 2022 and is expected to reach USD 2.0 billion in 2023.
b. The global poultry vaccines market is expected to grow at a compound annual growth rate of 7.4% from 2023 to 2030 to reach USD 3.3 billion by 2030.
b. Europe dominated the poultry vaccines market with a share of over 20% in 2022. This is attributable owing to an increase in consumption of poultry-related food products, consumer awareness concerning food safety, and high incidence of avian diseases.
b. Some key players operating in the poultry vaccines market include Merck & Co. Inc.; Zoetis; Boehringer Ingelheim International GmbH; Ceva; Hester Biosciences Limited; Elanco; Vaxxinova International BV; Venkys India; Calier; KM Biologics; and Phibro Animal Health Corporation among others
b. Key factors that are driving the poultry vaccines market growth include rising vaccination to curb avian disease outbreaks and soaring demand for poultry-related food products.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."